Mangoceuticals shares surge 56.11% premarket after announcing $73 million lawsuit against former technology consulting firm.

Mangoceuticals (MGRX) surged 56.11% in premarket trading following the announcement of a $2.5 million registered direct offering and private placement priced at the market under Nasdaq rules. The move, disclosed by the company within the last five hours, signals a strategic capital-raising effort to potentially fund operations or growth initiatives. While prior news, such as partnerships with Eli Lilly and Novo Nordisk for weight-management programs, had previously driven volatility, the immediate catalyst appears to be the recent equity offering, which may be interpreted as a vote of confidence in the company’s near-term prospects despite prior challenges like insider selling and legal disputes.